Allscripts (NASDAQ:MDRX) EVP Brian Farley sold 5,000 shares of Allscripts stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $13.73, for a total transaction of $68,650.00. Following the sale, the executive vice president now owns 240,672 shares in the company, valued at approximately $3,304,426.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ MDRX opened at $12.13 on Friday. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.97 and a quick ratio of 0.97. Allscripts has a one year low of $10.78 and a one year high of $16.13. The firm has a market capitalization of $2,233.51, a P/E ratio of 25.81, a PEG ratio of 1.59 and a beta of 1.23.
Allscripts (NASDAQ:MDRX) last released its quarterly earnings data on Thursday, February 15th. The software maker reported $0.18 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.18. The firm had revenue of $547.00 million during the quarter, compared to analyst estimates of $524.05 million. Allscripts had a positive return on equity of 7.36% and a negative net margin of 10.88%. The business’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 earnings per share. equities analysts anticipate that Allscripts will post 0.56 EPS for the current year.
Several brokerages have recently issued reports on MDRX. Zacks Investment Research raised shares of Allscripts from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. ValuEngine downgraded shares of Allscripts from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub downgraded shares of Allscripts from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Allscripts in a report on Sunday, January 28th. Finally, Citigroup initiated coverage on shares of Allscripts in a report on Thursday, January 4th. They issued a “buy” rating for the company. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $16.22.
Several hedge funds have recently made changes to their positions in MDRX. Zeke Capital Advisors LLC bought a new stake in shares of Allscripts during the fourth quarter worth $165,000. Avestar Capital LLC bought a new position in Allscripts in the fourth quarter valued at about $173,000. Sheaff Brock Investment Advisors LLC bought a new position in Allscripts in the third quarter valued at about $174,000. Quantitative Systematic Strategies LLC bought a new position in Allscripts in the fourth quarter valued at about $182,000. Finally, Crossmark Global Holdings Inc. bought a new position in Allscripts in the third quarter valued at about $187,000.
WARNING: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/insider-selling-allscripts-healthcare-solutions-inc-mdrx-evp-sells-5000-shares-of-stock.html.
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.